# We are IntechOpen,
# the world's leading publisher of
# Open Access books
# Built by scientists, for scientists

**6,900**
Open access books available

**185,000**
International authors and editors

**200M**
Downloads

**154**
Countries delivered to

Our authors are among the

**TOP 1%**
most cited scientists

**12.2%**
Contributors from top 500 universities

CLARIVATE ANALYTICS
**BOOK CITATION INDEX**
INDEXED

**WEB OF SCIENCE™**

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

## Interested in publishing with us?
## Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

# Predictors of the Response to Tolvaptan Therapy and Its Effect on Prognosis in Cirrhotic Patients with Ascites

Tomomi Kogiso, Kuniko Yamamoto,
Mutsuki Kobayashi, Yuichi Ikarashi,
Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii,
Etsuko Hashimoto and Katsutoshi Tokushige

Additional information is available at the end of the chapter

**Abstract**

*Aims*: The vasopressin V2 receptor antagonist, tolvaptan, has been reported to be effective in cirrhotic patients with ascites. Here, we evaluated predictors of the response to tolvaptan. *Methods*: A total of 97 patients with cirrhosis (60 males; median age, 63 years) who had been treated for ascites with oral tolvaptan were enrolled. Tolvaptan efficacy was defined as urine volume increase of ≥500 mL or a urine volume ≥2000 mL/day on the day following treatment. Normalization of the serum sodium (Na) level after 1 week of treatment and the posttreatment survival rate was analyzed. *Results*: Tolvaptan therapy resulted in effective urination in 67% of patients. A multivariate analysis revealed that the blood urea nitrogen/creatinine (BUN/Cr) ratio and urinary Na/potassium (Na/K) ratio were predictive of the tolvaptan response ($p < 0.05$). The serum Na level was 135 (121–145) mEq/L, and normal levels were recovered in 50.0% of the patients with an initial Na level of <135 mEq/L. The posttreatment survival rate was significantly higher in patients who responded to tolvaptan therapy ($p < 0.05$). *Conclusions*: The combination of the initial BUN/Cr and urine Na/K ratios and a normalized serum Na level after 1 week was predictive of a favorable outcome to tolvaptan therapy.

**Keywords:** vasopressin V2 receptor antagonist, tolvaptan, blood urea nitrogen/creatinine ratio, urine sodium/potassium ratio, serum sodium

## 1. Introduction

Ascites accumulation is commonly observed in decompensated liver cirrhosis [1]. The symptoms of ascites lead to a poor quality of life and prognosis [2]. Recently, the vasopressin V2 receptor

antagonist tolvaptan has been used for ascites treatment of cirrhosis in addition to spironolactone ± furosemide [3, 4]. The Japanese Society of Gastroenterology published evidence-based clinical practice guidelines in 2015 [5]. Tolvaptan is recommended for use before ascites drainage or administration of albumin because of its high efficacy irrespective of the serum albumin level [6]. While the serum sodium (Na) level is low in cirrhosis, it is increased in tolvaptan-treated patients because of free water clearance without accompanying Na elimination. In contrast, conventional diuretics promote hyponatremia and impair renal function. Thus, tolvaptan has benefits for the treatment of cirrhosis.

The mechanism underlying refractory ascites caused by liver cirrhosis has been hypothesized as one or more of the following [7, 8]: (1) hypo-osmotic pressure due to hypoalbuminemia; (2) a response to mesenteric and systemic vasodilation, accompanied by development of portal hypertension, which decreases the effective circulatory volume and depletes renal flow, leading to increased arginine vasopressin (AVP) release; increased AVP results in an increase in renin-angiotensin-aldosterone system activity; and (3) postsinusoidal obstruction and lymphatic edema. These multiple causative factors are associated with ascites accumulation.

Approximately 70% of tolvaptan-treated patients exhibit increased urination and achieve a reduction in body weight within 7–14 days [9, 10]. In addition to this short-term efficacy, tolvaptan also exerts long-term effects [11]. However, factors that predict the response to tolvaptan and its effect on prognosis are unclear. In this study, we focused on predictors of the tolvaptan response and the outcome of tolvaptan therapy.

## 2. Patients and methods

### 2.1. Patients

This was a single-center, retrospective observational study performed between September 2013 and March 2016. We enrolled a total of 97 Japanese cirrhotic patients (60 males, 62%) who received tolvaptan 3.75–7.5 mg/day (Samsca™; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) after hospitalization for ascites treatment. They were treated with conventional diuretics.

### 2.2. Method

The patients were classified as responders or nonresponders to tolvaptan therapy. Tolvaptan efficacy was defined as a urine volume increase of ≥500 mL or a urine volume ≥2000 mL/day on the day following tolvaptan treatment, as described by Ohki et al. with slight modifications [12]. The baseline characteristics of patients, including age, sex, medications, and laboratory parameters, were evaluated. We investigated the changes in body weight and the serum Na level after 1 week of treatment and evaluated laboratory parameters. Tolvaptan

was not used in patients with severe renal dysfunction (estimated glomerular filtration rate <15 mL/min/1.73 m$^2$ or a serum creatinine [Cr] level >3.5 mg/dL) or a hepatic coma scale score >II.

This study was conducted according to the principles of the Declaration of Helsinki, and the Institutional Review Board of Tokyo Women's Medical University Hospital (Tokyo, Japan) approved the study protocol (no. 3258-R). The results of this study, including figures and tables, were published in Hepatology Research [13] and were transferred with permission.

### 2.3. Statistical analysis

Data are presented as medians with minimum and maximum values. Significant differences between the two groups were assessed using the Mann–Whitney U-test and $\chi^2$ test. The Statistical Package for the Social Sciences software (SPSS Institute, 11.01.J, Chicago, IL, USA) was used for the statistical analyses. Statistical significance was considered at $p < 0.05$.

## 3. Results

### 3.1. Response to tolvaptan according to urination and body weight parameters

The median age of the 97 patients (62% male) receiving tolvaptan treatment was 63 years (range, 22–90 years; **Table 1**). The underlying liver diseases and frequency of other ascites treatments did not differ significantly. The median increase in urine volume on the day after treatment was 690 mL (range: −530 to +3490 mL), while the median urine volume was 1675 mL/day (range: 195–6630 mL/day). The distributions of urination and body weight changes and their correlations with the tolvaptan response are shown in **Figure 1(a)**. The change in body weight after 1 week of treatment was −1.5 kg (−17.2 to +6.2 kg). A total urine volume ≥2000 mL was achieved in 40% of cases and an increase in the urine volume in ~50% of cases (**Figure 1b**). Approximately 40% of cases achieved a ≥2.0 kg body weight reduction after 1 week of treatment. Overall, 67% of the cases achieved the desired level of urination. In cases who responded to tolvaptan, the platelet count, urine Na level, and urine Na/potassium (K) ratio were higher, and the blood urea nitrogen (BUN)/Cr ratio was lower (**Table 2**). The serum Na level was 135 (121–145) mEq/L, and 39.2% of cases had an Na level of <135 mEq/L.

### 3.2. Urination-based predictors of the response to tolvaptan

Multivariate analysis revealed that the BUN/Cr ratio (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.006–1.174; $p < 0.05$) and urine Na/K ratio (OR, 0.59; 95% CI, 0.366–0.855; $p < 0.01$) were predictors of the tolvaptan response (**Table 3**). In particular, patients who satisfied both

|  | Total ($n$ = 97) | Responder ($n$ = 65) | Nonresponder ($n$ = 32) | $p$-value |
|---|---|---|---|---|
| Age (years) | 63 (22–90) | 62 (22–90) | 63 (37–84) | 0.21 |
| Sex (% of males) | 62 | 66 | 53 | 0.21 |
| Underlying hepatitis (%) (viral/metabolic/ PBC) | 37/39/9 | 32/43/11 | 47/31/6 | 0.29 |
| Complication (%) (varices/HCC/hepatic encephalopathy) | 67/35/23 | 71/35/18 | 59/34/31 | 0.37 |
| Diuretics |  |  |  |  |
| Furosemide dose (mg/ day) | 20 (0–160) | 20 (0–160) | 20 (0–80) | 0.96 |
| Spironolactone dose (mg/day) | 50 (0–400) | 50 (0–400) | 50 (0–400) | 0.97 |
| BCAA (%) | 90 | 89 | 91 | 0.11 |
| Administration of albumin (%) | 62 | 63 | 59 | 0.65 |
| CART or drainage (%) | 41 | 38 | 47 | 0.43 |
| Prognosis; death or transplantation (%) | 45 | 37 | 63 | 0.03 |

*Notes*: PBC, primary biliary cholangitis; HCC, hepatocellular carcinoma; BCAA, branched-chain amino acid; CART, cell-free and concentrated ascites reinfusion therapy.

**Table 1.** Baseline characteristics of the patients.



**Figure 1.** Urine volume and body weight response after tolvaptan treatment. (a) Distributions of urine volume after 1 day, and change in body weight after 1 week, of tolvaptan treatment. Circle, responder; cross, nonresponder. (b) The percentage of urination and body weight reduction responded to a tolvaptan therapy. Urine volume 1 day after, and change in body weight 1 week after, tolvaptan treatment was correlated with the tolvaptan response (a). A body weight reduction of ≥2.0 kg was found in 40% of cases, and a urine volume ≥2000 mL and a urine volume increase ≥500 mL were found in 67% of patients in response to tolvaptan therapy (b).

| | Total (*n* = 97) | Responder (*n* = 65) | Nonresponder (*n* = 32) | *p* value |
|---|---|---|---|---|
| Albumin (g/dL) | 2.5 (1.5–4.2) | 2.5 (1.5–4.2) | 2.4 (1.9–3.5) | 0.88 |
| Total bilirubin (mg/dL) | 1.8 (0.3–52.4) | 1.5 (0.5–33.0) | 2.2 (0.3–52.4) | 0.73 |
| Platelet count (×10$^4$ μL$^{-1}$) | 8.6 (1.5–42.4) | 9.0 (1.5–42.4) | 6.4 (2.1–23.9) | 0.05 |
| Prothrombin time (%) | 54.5 (16.3–90.3) | 54.5 (16.3–90.3) | 52.6 (22.6–89.0) | 0.70 |
| Ammonia (mg/dL) | 69 (25–269) | 70 (25–269) | 63 (29–212) | 0.97 |
| *α*-Fetoprotein (ng/mL) | 4 (1–29,292) | 4 (1–4510) | 6.5 (1–29,292) | 0.36 |
| DCP (mAU/mL) | 75 (3–4994) | 42 (3–4994) | 324 (10–1788) | 0.61 |
| BUN (mg/dL) | 23.4 (5.5–125.3) | 21 (5.5–63.3) | 27 (12.0–125.3) | 0.02 |
| Creatinine (mg/dL) | 1.07 (0.20–3.30) | 1.00 (0.42–2.12) | 1.17 (0.50–3.30) | 0.13 |
| eGFR (mL/min/1.73 m²) | 50.0 (15.0–250.6) | 50.3 (18–250.6) | 46.2 (15.0–108.6) | 0.15 |
| Serum Na (mEq/L) | 135 (121–145) | 136 (122–145) | 133 (121–144) | 0.06 |
| Serum K (mEq/L) | 4.2 (2.8–6.1) | 3.9 (2.8–5.3) | 4.3 (3.1–6.1) | 0.06 |
| Serum osmolarity (mOsm/L) | 281 (100–317) | 283 (100–317) | 279 (256–299) | 0.68 |
| Urine osmolarity (mOsm/L) | 404 (116–938) | 405 (116–938) | 388 (233–715) | 0.63 |
| Urinary Na (mEq/L) | 61 (7–256) | 69.5 (10–256) | 39 (7–108) | <0.01 |
| Urinary K (mEq/L) | 21 (6–72) | 20 (6–72) | 22 (13–48) | 0.72 |
| 24 h creatinine clearance (mL/min) | 51.2 (7.6–124.0) | 52.8 (12.4–124.0) | 44.1 (7.6–92.9) | 0.12 |
| BUN/creatinine ratio | 22.5 (6.83–138.5) | 21 (5.5–138.5) | 23.7 (14.4–48.3) | 0.01 |
| Urine Na/K ratio | 2.53 (0.22–25.6) | 3.31 (0.35–25.6) | 2.01 (0.22–5.13) | <0.01 |
| Child-pugh score | 10 (7–14) | 10 (7–13) | 10 (8–14) | 0.23 |
| Model for end-stage liver disease score | 14 (7–31) | 14 (7–31) | 16 (8–31) | 0.37 |

*Notes*. DCP; des-γ-carboxy prothrombin, BUN; blood urea nitrogen; eGFR, estimated glomerular filtration rate; Na/K; sodium/potassium.

**Table 2.** Laboratory data at initiation of tolvaptan treatment.

| Parameter | Odds ratio | 95% confidence interval | *p*-value |
|---|---|---|---|
| BUN/Cr ratio | 1.08 | 1.006–1.174 | <0.05 |
| Urine Na/K ratio | 0.59 | 0.366–0.855 | <0.01 |
| Serum K | 1.41 | 0.537–3.893 | n.s |
| Serum Na | 0.96 | 0.854–1.080 | n.s |
| Platelet count | 0.95 | 0.839–1.051 | n.s |

*Notes*. Na/K, sodium/potassium; n.s, not significant.

**Table 3.** Multivariate analysis of parameters predicting a urination response to tolvaptan therapy.

| | | Urine Na/K ratio | |
|---|---|---|---|
| | | <3.09 (*n* = 47) | ≥3.09 (*n* = 30) |
| BUN/Cr ratio | <17.5 (*n* = 23) | 10/12 (83.3%) | 8/8 (100.0%) |
| | ≥17.5 (*n* = 64) | 13/33 (39.4%) | 19/22 (86.3%) |

*Notes.* BUN/Cr, blood urea nitrogen/creatinine; Na/K, sodium/potassium.

**Table 4.** Response to tolvaptan according to BUN/Cr and urine Na/K ratios.



**Figure 2.** Distributions of the BUN/Cr ratio and urinary Na/K ratio and changes in urine volume and body weight. (a) Distributions of the BUN/Cr ratio and urinary Na/K ratio according to the tolvaptan response. Circle, responder, cross, nonresponder; framed square, BUN/Cr ratio ≥17.5, and urine Na/K ratio <3.09. Changes in (b) urine volume and (c) body weight in patients with and those without a BUN/Cr ratio ≥17.5 and urine Na/K ratio <3.09. Patients without a BUN/Cr ratio ≥17.5 and urine Na/K ratio <3.09 showed greater reductions in urine volume after 1 day (b) and in body weight after 1 week of treatment (c). BUN/Cr, blood urea nitrogen/creatinine; Na/K, sodium/potassium, *$p < 0.01$, **$p < 0.05$.

**Figure 3.** Survival rate of patients with and without a response to tolvaptan and the BUN/Cr and urine Na/K ratios. Patients who responded to tolvaptan therapy (a) and who did not have a BUN/Cr ratio ≥17.5 or urine Na/K ratio <3.09 (b) showed a significantly higher survival rate compared with nonresponders. BUN/Cr, blood urea nitrogen/creatinine; Na/K, sodium/potassium, $*p < 0.01$, $**p < 0.05$.

criteria of a BUN/Cr ratio <17.5 and urine Na/K ratio ≥3.09 achieved high tolvaptan response rates ($n = 8$, 100%; **Table 4**). In contrast, patients with a BUN/Cr ratio ≥17.5 and urine Na/K ratio <3.09 exhibited an extremely poor response (**Figure 2a**, framed area). In those patients who did not meet these criteria, urination and body weight reductions were observed (**Figure 2b** and **c**).

### 3.3. Prognosis after tolvaptan treatment

Regarding the mortality rate, 44 subjects died (45.4%). The survival rate was higher in patients who responded to tolvaptan therapy, as estimated by the Kaplan–Meier analysis (**Figure 3a**, $p < 0.01$). Patients with a BUN/Cr ratio <17.5 or urine Na/K ratio ≥3.09 showed a significantly higher survival rate than that of those who did not meet these criteria (**Figure 3b**, $p < 0.05$).

After 1 week of treatment, 70.1% of the patients achieved a normal serum Na level. These patients showed a significantly higher survival rate ($p < 0.05$). Among the patients with an initial Na level of <135 mEq/L ($n = 38$), 50.0% achieved a normal Na level after tolvaptan therapy and showed a significantly higher survival rate than that of patients without normalized Na levels ($p < 0.05$).

## 4. Discussion

The results suggest that the initial BUN/Cr and urine Na/K ratios and a normalized serum Na level after 1 week of treatment is predictive of a tolvaptan response in cirrhosis patients. The

patients showing a response to tolvaptan in terms of increased urination or serum Na level had prolonged survival and a better prognosis.

Representative factors predicting a response to tolvaptan are shown in **Table 5**. Free water clearance [14], aquaporin-2/AVP [15], and urinary Na excretion [16] were reported to be predictors of a tolvaptan response in patients with cirrhosis. The combination of BUN/Cr and urine Na/K ratios was the first reported predictor of a tolvaptan response.

Regarding prognosis, tolvaptan reduced the rate of inhospital mortality [17] and evidenced longer mortality same as other diuretics in heart failure patients [18], although no study has assessed these parameters in cirrhotic patients. In our study, patients with a BUN/Cr <17.5 or urine Na/K ≥3.09 showed high response rates. Approximately 50.0% of tolvaptan-treated patients reached a normal serum Na level after 1 week of tolvaptan therapy. Patients who responded to tolvaptan exhibited prolonged survival compared with those who did not. Tolvaptan may improve the prognosis.

Tolvaptan has been reported to delay the onset of end-stage renal disease and to be associated with a low rate of renal function deterioration [19, 20]. Therefore, early initiation of tolvaptan is recommended to protect renal function and improve prognosis.

However, our study had limitations because hepatocellular carcinoma (HCC) affects the mortality rate of patients with cirrhosis. Therefore, HCC cases must be excluded from prognostic analyses.

| Author | Journal | Year | Predictor | Disease |
|---|---|---|---|---|
| Imamura et al. [21] | Circ J. | 2013 | Urine osmolality and percentage decrease in urine osmolarity | Heart failure |
| Imamura et al. [22] | Circ J. | 2014 | Urine aquaporin-2 (AQP2)/plasma arginine vasopressin | Heart failure |
| Okayama et al. [23] | Am J Cardiovasc Drugs | 2015 | Blood urea nitrogen/creatinine (BUN/Cr) ratio | Heart failure |
| Shimizu et al. [24] | Nephrology (Carlton) | 2015 | Urine urea nitrogen/BUN ratio | Heart failure |
| Iwatani et al. [25] | Nephron | 2015 | Urine osmolarity | Chronic kidney disease |
| Miyaaki et al. [14] | Biomed Rep. | 2015 | Free water clearance | Liver cirrhosis |
| Nakanishi et al. [15] | J Gastroenterol. | 2016 | Urinary AQP2/Cr ratio | Liver cirrhosis |
| Chishina et al. [26] | Dig Dis. | 2016 | Serum BUN and serum Cr | Liver cirrhosis |
| Imamura et al. [27] | Int J Mol Sci. | 2016 | Urine AQP2 | Heart failure |
| Kogiso et al. [13] | Hepatol Res. | 2016 | Serum BUN/Cr and urine sodium/potassium ratios | Liver cirrhosis |

**Table 5.** Representative predictors of the response to tolvaptan therapy.

## 5. Conclusion

In addition to the combination of an initial BUN/Cr ratio <17.5 and urine Na/K ratio ≥3.09, a normalized serum Na level after 1 week of tolvaptan therapy was predictive of a favorable outcome in cirrhotic patients with hyponatremia and ascites treated with tolvaptan.

## Author details

Tomomi Kogiso*, Kuniko Yamamoto, Mutsuki Kobayashi, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Etsuko Hashimoto and Katsutoshi Tokushige

*Address all correspondence to: kogiso.ige@twmu.ac.jp

Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women's, Medical University, Shinjuku-ku, Tokyo, Japan

## References

[1] Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: Natural history and prognostic factors. Hepatology. 1987;**7**:122-128

[2] Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterology and Hepatology. 2006;**4**:1385-1394. DOI: 10.1016/j.cgh.2006.08.007

[3] Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983;**84**:961-968

[4] Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet. 1966;**1**:1049-1052

[5] Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology. 2016;**51**:629-650. DOI: 10.1007/s00535-016-1216-y.

[6] Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H, Kobayashi H. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. Journal of Gastroenterology. 2015;**50**:1047-1053. DOI: 10.1007/s00535-015-1052-5.

[7]    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;**8**:1151-1157

[8]    Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: Clinical implications and new therapeutic options. Clinical Science (London). 2012;**123**:225-239. DOI: 10.1042/CS20120030

[9]    Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, Sata M, Yoshihara H, Ono N, Murawaki Y. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. Journal of Gastroenterology. 2010;**45**:979-987. DOI: 10.1007/s00535-010-0240-6

[10]   Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K; ASCITES 14-Day Administration Study Group. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. The Journal of International Medical Research. 2013;**4**:835-847. DOI: 10.1177/0300060513480089

[11]   Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatology Research. 2016;**46**:E194-E200. DOI: 10.1111/hepr.12547

[12]   Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World Journal of Hepatology. 2015;**7**:1685-1693. DOI: 10.4254/wjh.v7.i12.1685

[13]   Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatology Research. 2016. In press. DOI: 10.1111/hepr.12822.

[14]   Miyaaki H, Nakamura Y, Ichikawa T, Taura N, Miuma S, Shibata H, Honda T, Nakao K. Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. Biomedical Reports. 2015;**3**:884-886. DOI: 10.3892/br.2015.521

[15]   Nakanishi H, Kurosaki M, Hosokawa T, Takahashi Y, Itakura J, Suzuki S, Yasui Y, Tamaki N, Nakakuki N, Takada H, Higuchi M, Komiyama Y, Yoshida T, Takaura K, Hayashi T, Kuwabara K, Sasaki S, Izumi N. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of Gastroenterology. 2016;**51**:620-627. DOI: 10.1007/s00535-015-1143-3

[16]   Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatology Research. 2017;**47**:E14-E21. DOI: 10.1111/hepr.12716

[17]   Yoshioka K, Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, Matsumura A, Yoshida K, Hashimoto Y. Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome. Journal of Cardiology. 2016;**67**:406-411. DOI: 10.1016/j.jjcc.2015.12.004

[18] Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y. Long-term effects and prognosis in acute heart failure treated with tolvaptan: The AVCMA trial. BioMed Research International. 2014;**2014**:704289. DOI: 10.1155/2014/704289

[19] Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. Journal of Cardiology. 2016;**67**:399-405. DOI: 10.1016/j.jjcc.2015.09.020

[20] Mori T, Ohsaki Y, Oba-Yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatology Research. 2017;**47**:11-22. DOI: 10.1111/hepr.12700

[21] Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Kyo S, Komuro I. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circulation Journal. 2013;**77**:1208-1213

[22] Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circulation Journal. 2014;**78**:2240-2249

[23] Okayama D, Suzuki T, Shiga T, Minami Y, Tsuruoka S, Hagiwara N. Blood urea nitrogen/creatinine ratio and response to tolvaptan in patients with decompensated heart failure: A retrospective analysis. American Journal of Cardiovascular Drugs. 2015;**15**:289-293. DOI: 10.1007/s40256-015-0121-8

[24] Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure. Nephrology (Carlton). 2015;**20**:405-412

[25] Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: A retrospective, observational study. Nephron. 2015;**130**:8-12. DOI: 10.1159/000381859

[26] Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M. Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Digestive Diseases and Sciences. 2016;**34**:659-664. DOI: 10.1159/000448828

[27] Imamura T, Kinugawa K. Urine aquaporin-2: A promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. International Journal of Molecular Sciences. 2016;**17**(105):1-7. DOI: 10.3390/ijms17010105